• Source: CP-154,526

CP-154,526 is a potent and selective antagonist of the corticotropin releasing hormone receptor 1 developed by Pfizer.
CP-154,526 is under investigation for the potential treatment of alcoholism.




See also


Antalarmin
Pexacerfont
Corticotropin releasing hormone antagonist




References






Further reading


Seymour PA, Schmidt AW, Schulz DW (2006). "The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review". CNS Drug Reviews. 9 (1): 57–96. doi:10.1111/j.1527-3458.2003.tb00244.x. PMC 6741649. PMID 12595912.
Navarro-Zaragoza J, Núñez C, Laorden ML, Milanés MV (May 2010). "Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal". Molecular Pharmacology. 77 (5): 864–73. doi:10.1124/mol.109.062463. PMID 20159948. S2CID 18588298.
Kobayashi T, Kiyokawa Y, Takeuchi Y, Mori Y (September 2011). "Pretreatment with CP-154526 blocks the modifying effects of alarm pheromone on components of sexual behavior in male, but not in female, rats". Chemical Senses. 36 (7): 623–32. doi:10.1093/chemse/bjr017. PMID 21502338.




External links


CP+154526 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

Kata Kunci Pencarian:

• CP-154,526
• Corticotropin-releasing hormone
• Antalarmin
• Fear
• List of signaling peptide/protein receptor modulators
• Corticotropin-releasing hormone antagonist
• Pexacerfont
• Signaling peptide receptor